Gadolinium news

All news on Gadolinium: plants, production capacities, investments and involved companies in Europe.

27 August 2025
FDA Reviews Bayer's Gadoquatrane Application
Gadoquatrane, a low-dose MRI contrast agent, shows positive Phase III results. It's under review in the U.S., Japan, and EU for use in adults and children, including neonates.
10 July 2025
Bayer Seeks EU Approval for Gadoquatrane
Gadoquatrane, a low-dose MRI contrast agent, shows positive Phase III results. EU approval could reduce gadolinium exposure by 60% compared to current standards.

Who will be producing Gadolinium in the future?

Find out with chemXplore Analytics